Why the study?
Does oral administration of compound 74 inhibit thromboxane synthase and block thromboxane receptors in conscious dogs?
Does oral administration of compound 74 inhibit thromboxane synthase and block thromboxane receptors in conscious dogs?
Compound 74 acts as a dual thromboxane synthase inhibitor and receptor antagonist, effectively inhibiting platelet aggregation in a preclinical canine model.
Supports advancement of compound 74 to clinical testing; leaves open translation of dual thromboxane effects to human cardiovascular outcomes.
The design of a series of dual thromboxane synthase inhibitor/thromboxane receptor antagonists based on a 3-[2-[(arylsulfonyl)amino]ethyl]benzenepropanoic acid thromboxane receptor antagonist template is described. Introduction of a 5-(1H-imidazol-1-ylmethyl), a 5-(3-pyridinyl-methyl), or a 5-(3-pyridinyloxy) substituent leads to dual agents with thromboxane synthase inhibitory activity comparable with that of dazmegrel (7). In addition, 3-pyridinylalkyl substituents also make a significant contribution to thromboxane receptor binding. Oral administration of compound 74 (5 mg/kg) to conscious dogs produces long-lasting thromboxane synthase inhibition and thromboxane receptor blockade as measured by inhibition of U46619-induced platelet aggregation ex vivo.
No takes yet. Share an insight, caveat, or question.
Dickinson et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: